Make your money go further for just 25p per day

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020 · AstraZeneca (AZN)  · GSK (GSK)  · Tristel (TSTL) 

Coronavirus Pharma and Biotech UK

GSK logo

The pharmaceutical industry has enjoyed a strong 2020. These are companies which – in the eyes of investors – could really benefit from the period of immense disruption.


But financial results from the UK’s two pharma giants reveal that there is another trend in play here: focus on Covid-19 has dented demand for other, less pressing treatments. Routine GP appointments, prescriptions and subsequently pharma sales have declined in the last three months.

That was reflected in half year results at GlaxoSmithKline (LON: GSK) where an 8% like-for-like decline in sales to £7.6bn came in behind analyst estimates. Falling demand was experienced across all three…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on AstraZeneca

Overhyped perhaps - but don’t ignore AI!

03/07/2024 · Company Insights

Is AI overhyped? Of course it is, but there are still plenty of opportunities for investors…


AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020 · Company Insights

The pharmaceutical industry has enjoyed a strong 2020. These are companies which – in the eyes…


More on GSK

Income Boosters update - 7.8% dividend yield

07/03/2025 · Portfolio

Our high yield portfolio boasts a potential 7.8% dividend yield. We review recent results and discuss…


Overhyped perhaps - but don’t ignore AI!

03/07/2024 · Company Insights

Is AI overhyped? Of course it is, but there are still plenty of opportunities for investors…


More on Tristel

US approval | Successful sale | Angling success

14/05/2025 · Company Insights

News covered here includes our assessment of pleasing results from a specialist fishing tackle retailer, although…


Positive news from the USA for a change…

10/04/2025 · Company Insights

News covered here includes our assessment of results from an elderly producer of ceramics, which many…


More Company Insights

Whopping warning!

30/05/2025 · hVIVO

Litigation issues | Modest valuation | Publishing doubts

Bonkers Bargains: shares bounce on trading update

22/05/2025 · James Cropper

Sign-up to our free email updates

SIGN UP